Cardinal Health's profitability appears structurally improving, with gross margin expanding 120 basis points from 3.1% in fiscal 2024 Q3 to 4.3% in fiscal 2026 Q4 and operating margin rising to 1.1% on positive SG&A leverage, while the valuation gap between a 31.6x trailing P/E and 18.2x forward P/E suggests the market…
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated sharply from 22.4% in fiscal 2026 Q1 to 6.1% in Q4, yet gross margin expanded to 4.3% and operating margin to 1.1%, suggesting mix-driven profitability gains are outpacing top-line momentum.
Cardinal Health is actively combating opioid misuse in America, reinforcing its role in securing the pharmaceutical supply chain.
Q4 revenue of $64 billion marked an 8.4% beat, with the strongest sequential acceleration in 7 quarters, driven by 32% growth in Specialty Solutions.
CAH's trailing P/E of 24.57 and forward P/E of 16.92 suggest potential undervaluation relative to growth prospects.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $3.26+10.9% vs $2.94 | $67.5B+1.3% vs $66.7B |
Q3 2026 Aug 11, 2026 | $2.91+20.2% vs $2.42 | $63.7B-2.3% vs $65.2B |
Q2 2026 Apr 30, 2026 | $3.17+13.6% vs $2.79 | $60.9B-1.9% vs $62.1B |
Q1 2026 Feb 5, 2026 | $2.63+12.4% vs $2.34 | $65.6B+0.8% vs $65.1B |
I present 69 Dividend Champions with Dividend Safety scores of 8+ and rank them using my 9F Quality Scores system. Twenty-two featured Dividend Champions are undervalued, while 21 are overvalued. Forty-nine have quality scores ≥ 7.0, indicating high quality. Top candidates by style: BRO and BMI for growth; BRO, BMI, and RGLD (below $262) for total return; CTBI for income; CAT for past performance.
Cardinal Health NYSE: CAH raised its fiscal 2027 earnings outlook after reporting double-digit profit growth in its pharmaceutical and specialty segment and its other growth businesses for the first quarter.
Cardinal Health raises its fiscal 2027 earnings outlook as specialty growth, strong generics demand and customer renewals offset medical distribution pressures.
Shares of Cardinal Health, Inc. (NYSE: CAH - Get Free Report) reached a new 52-week high during trading on Thursday following a better than expected earnings announcement. The company traded as high as $268.00 and last traded at $280.7730, with a volume of 2,248 shares changing hands. The stock had previously closed at $261.93. The company
Benchmark CAH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cardinal Health, Inc. (CAH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $271.72 | $63.64B | 34.82 | 14.23% | 0.71% | — | 0.76% | |
| $1060.84 | $123.8B | 26.34 | 12.36% | 1.12% | — | 0.29% | |
| $86.05 | $9.8B | 23.00 | 4.03% | 3.07% | 8.83% | — | |
| $0.20 | $15.62M | -0.01 | -74.19% | -6.72% | — | — | |
| $190.02 | $5.8B | 15.80 | -8.47% | 4.72% | 16.68% | 2.9% | |
| $276.22 | $664.92B | 42.02 | 6.05% | 16.2% | 19.55% | 1.85% |
Cardinal Health, Inc. (CAH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cardinal Health, Inc. (CAH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 1, 2026·SEC
Aug 11, 2026·SEC
Aug 11, 2026·SEC
Get notified when CAH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cardinal Health, Inc. (CAH) stock FAQ — growth, dividends, profitability & financials explained
Cardinal Health, Inc. (CAH) reported $257.75B in revenue over the trailing twelve months. Revenue was $254.25B in fiscal year 2026. That is 1282% more than the $18.39B of fiscal year 1997.
Cardinal Health, Inc. (CAH) grew revenue by 10.0% over the trailing twelve months, compared with the twelve months before.
Yes. Cardinal Health, Inc. (CAH) earned $1.82B in net income over the trailing twelve months (a 0.7% net margin).
Yes. Cardinal Health, Inc. (CAH) pays a dividend that yields 0.76% at the current price, a small yield.
Cardinal Health, Inc. (CAH) generated $4.90B in free cash flow over the trailing twelve months.
